Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

05.07.2016 | brief report

Cutaneous Langerhans cell histiocytosis

The spectrum of a rare cutaneous neoplasia

verfasst von: Prof. Dr. Uwe Wollina, Dana Langner, Gesina Hansel, Jacqueline Schönlebe

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 9-10/2018

Einloggen, um Zugang zu erhalten

Summary

Langerhans cell histiocytosis (LCH) is a rare disorder that is now recognized as a true malignancy of dendritic Langerhans cells. Various somatic mutations have been discovered for BRAF and MAP kinases. The clinical variability is remarkable. A very rare variant is cutaneous LCH without internal organ manifestations. We present a case series of cutaneous LCH illustrating the spectrum of clinical symptoms, treatment, and disease course. Cutaneous LCH needs a careful investigation of possible internal involvement and a long follow-up since second malignancies may develop over time. Overtreatment should be avoided, since too-aggressive treatment will not improve the outcome.
Vorheriger Artikel Psychosocial aspects associated with use of sunscreen, natural sunlight exposure, and artificial tanning
Nächster Artikel Mosaic capillaroscopic findings in systemic sclerosis
Literatur
1.
Zinn DJ, Chakraborty R, Allen CE. Langerhans cell histiocytosis: emerging insights and clinical implications. Oncology (Williston Park, NY). 2016;30:122.
2.
Satoh T, Smith A, Sarde A, Lu HC, Mian S, Trouillet C, et al. B‑RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS ONE. 2012;7:e33891.CrossRefPubMedPubMedCentral
3.
Kansal R, Quintanilla-Martinez L, Datta V, Lopategui J, Garshfield G, Nathwani BN. Identification of the V600D mutation in exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis. Genes Chromosomes Cancer. 2013;52:99–106.CrossRefPubMed
4.
Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124:1655–8.CrossRefPubMed
5.
Nelson DS, Halteren A van, Quispel WT, Bos C van den, Bovée JV, Patel B, et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2015;54:361–8.CrossRefPubMed
6.
Sholl LM, Hornick JL, Pinkus JL, Pinkus GS, Padera RF. Immunohistochemical analysis of langerin in Langerhans cell histiocytosis and pulmonary inflammatory and infectious diseases. Am J Surg Pathol. 2007;31:947–52.CrossRefPubMed
7.
Morren MA, Vanden Broecke K, Vangeebergen L, Sillevis-Smitt JH, Berghe P van den, Hauben E, et al. Diverse cutaneous presentations of Langerhans cell histiocytosis in children: a retrospective cohort study. Pediatr Blood Cancer. 2016;63:486–92.CrossRefPubMed
8.
Bansal M, Srivastava VK, Bansal R, Gupta V, Bansal M, Patne S. Severe periodontal disease manifested in chronic disseminated type of Langerhans cell histiocytosis in a 3‑year old child. Int J Clin Pediatr Dent. 2014;7:217–9.CrossRefPubMed
9.
Tucker AT, Emerson AN, Wyatt JP, Brodell RT. Case report: diaper dermatitis presenting as pustules. J Drugs Dermatol. 2014;13:1153–4.PubMed
10.
Kim JE, Kim BJ, Kang H. Solitary congenital erosion in a newborn: report of a solitary congenital self-healing reticulohistiocytosis. Ann Dermatol. 2014;26:250–3.CrossRefPubMedPubMedCentral
11.
Mandel VD, Ferrari C, Cesinaro AM, Pellacani G, Forno C del. Congenital “self-healing” Langerhans cell histiocytosis (Hashimoto-Pritzker disease): a report of two cases with the same cutaneous manifestations but different clinical course. J Dermatol. 2014;41:1098–101.CrossRefPubMed
12.
Ng SS, Koh MJ, Tay YK. Cutaneous Langerhans cell histiocytosis: study of asian children shows good overall prognosis. Acta Paediatr. 2013;102:e514–e518.CrossRefPubMed
13.
Ness MJ, Lowe GC, Davis DM, Hand JL. Narrowband ultraviolet B light in Langerhans cell histiocytosis: a case report. Pediatr Dermatol. 2014;31:e10–e12.CrossRefPubMed
14.
Wollina U, Kaatz M, Krönert C, Schönlebe J, Schmalenberg H, Schreiber G, et al. Cutaneous Langerhans cell histiocytosis with subsequent development of haematological malignancies. Report of two cases. Acta Dermatovenerol Alp Pannonica Adriat. 2006;15:79–84.PubMed
15.
Podjasek JO, Loftus CG, Smyrk TC, Wieland CN. Adult-onset systemic Langerhans cell histiocytosis mimicking inflammatory bowel disease: the value of skin biopsy and review of cases of Langerhans cell histiocytosis with cutaneous involvement seen at the Mayo Clinic. Int J Dermatol. 2014;53:305–11.CrossRefPubMed
16.
Shahidi-Dadras M, Saeedi M, Shakoei S, Ayatollahi A. Langerhans cell histiocytosis: an uncommon presentation, successfully treated by thalidomide. Indian J Dermatol Venereol Leprol. 2011;77:587–90.CrossRefPubMed
17.
Edelbroek JR, Vermeer MH, Jansen PM, Stoof TJ, Linden MM van der, Horváth B, et al. Langerhans cell histiocytosis first presenting in the skin in adults: frequent association with a second haematological malignancy. Br J Dermatol. 2012;167:1287–94.CrossRefPubMed
18.
Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:1495–500.CrossRefPubMed
19.
Charles J, Beani JC, Fiandrino G, Busser B. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation. J Am Acad Dermatol. 2014;71:e97–e99.CrossRefPubMed
20.
Haroche J, Cohen-Aubart F, Emile JF, Donadieu J, Amoura Z. Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. J Am Acad Dermatol. 2015;73:e29–e30.CrossRefPubMed
Metadaten
Titel
Cutaneous Langerhans cell histiocytosis
The spectrum of a rare cutaneous neoplasia
verfasst von
Prof. Dr. Uwe Wollina
Dana Langner
Gesina Hansel
Jacqueline Schönlebe
Publikationsdatum
05.07.2016
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 9-10/2018
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-016-0460-3

Weitere Artikel der Ausgabe 9-10/2018

Psychosocial aspects associated with use of sunscreen, natural sunlight exposure, and artificial tanning

  • original article

Dog bite injury — alar repair with composite graft

  • case report

Indikationen und Kontraindikationen der modernen Kompressionstherapie

  • übersicht

Palmar hyperhidrosis treated by noninvasive ultrasound stellate ganglion block

  • case report

Histopathologic pitfalls of Mohs micrographic surgery and a review of tumor histology

  • review

Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology

  • review